New use of aesculin in preventing and/or treating cardiovascular disease

A technology for cardiovascular and cerebrovascular diseases, qinpina, which is applied in cardiovascular system diseases, metabolic diseases, urinary system diseases, etc. Development prospects, prevention and treatment formation and development, effect of simple extraction process

Active Publication Date: 2008-02-27
INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI
View PDF0 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

So far, we have not seen any research reports on atherosclerosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • New use of aesculin in preventing and/or treating cardiovascular disease
  • New use of aesculin in preventing and/or treating cardiovascular disease
  • New use of aesculin in preventing and/or treating cardiovascular disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0054] Embodiment 1: According to the co-incubation of bovine serum albumin (Bovine Serum Albumin, BSA) and glyoxal (Glyoxyl) to generate AGEs, the sample is incubated with BSA and Glyoxyl together, with aminoguanidine (AGN) as the positive drug, by The change of the fluorescence value of AGEs was used to judge the inhibitory effect of the sample on AGEs. Through the screening of AGEs inhibitors and cracking agents on 4800 samples, it was found that aperetin has good AGEs inhibitory effect (half inhibitory concentration is 2ng / ml) and cracking effect (half inhibitory concentration<1ng / ml).

Embodiment 2

[0055] Example 2: The blood-lipid-lowering effect of acetaminophen on rats with experimental atherosclerosis.

[0056] Male SD rats were randomly divided into

[0057] Blank control group (give common feed feeding) namely control,

[0058] The hyperlipidemia model group is model,

[0059] AGEs model group is AGE model,

[0060] Qinpi low-dose group (10mg / kg), that is, QP10mg / kg,

[0061] Qinpi high-dose group (50mg / kg), that is, QP50mg / kg,

[0062] Simvastatin (0.35mg / kg) positive control group is Tatin3.5mg / kg.

[0063] Rats were fed with high-fat diet for 90 days, and at the same time, they were fed with the test drug every morning; sodium cholate (300 mg / kg) and propylthiouracil (150 mg / kg) were fed with it in the afternoon; AGEs model group, Qinpi low-dose AGEs (5 mg / kg) were injected intravenously every week in the control group and the Qinpi high-dose group. Serum total cholesterol (CHO), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholest...

Embodiment 3

[0065] Example 3: The effect of acetaminophen on serum superoxide dismutase (SOD) in rats with experimental atherosclerosis.

[0066] The dosing regimen is exactly the same as that in Example 2, and blood is taken at 12 weeks of administration to detect serum SOD.

[0067] The results showed that the activity of SOD in the serum of the AGEs model group and the hyperlipidemia model group was significantly lower than that of the blank control group; the activity of SOD in the acetaminophen administration group could be significantly increased.

[0068] The result shows that alopecia (10mg / kg), alopecia (50mg / kg) groups can significantly increase the SOD activity of hyperlipidemic rats; Balance plays an important role and can scavenge superoxide anion free radicals. See Figure 5 for details.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an application of Esculin to prevent and/or treat terminal advanced glycation end-products disease and Cardio-Cerebral-Vascular Disease, especially for the coronary atherosclerosis and arterial atherosclerosis, which is characterized by the following: cracking of terminal advanced glycation end-products, eliminating superoxide anion radical; protecting organism cell from Free-Raducak Injury; antagonizing Experimentative Hyperlipoidemia and decreasing Carotid Atherosclerosis formation. The invention has low toxicity, easy extraction, vast resource, good prospects, which is a perfect Chinese Herb to cure Cardio-Cerebral-Vascular Disease.

Description

technical field [0001] The present invention relates to the prevention and / or treatment of fruticelin and its use in medicines for diseases related to advanced glycation end products and cardiovascular and cerebrovascular diseases, especially in the preparation of medicines for preventing and treating atherosclerosis. technical background [0002] As we all know, cardiovascular and cerebrovascular diseases are the diseases with the highest mortality rate in the world. Atherosclerosis is the main pathological basis and main cause of many cardiovascular and cerebrovascular diseases. It is a pathological process of arterial mechanical stenosis caused by the interaction of arterial wall cells, extracellular matrix, blood components (monocytes, platelets, and low-density lipoprotein), local hemodynamics, environment, and genetics. Complex, multifactorial diseases, the molecular and cellular mechanisms of their pathogenesis are still poorly understood. [0003] Post-transcription...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61P9/10A61P3/06A61P3/10A61P13/12
Inventor 杜冠华张东明方莲花杨敬芝孙缅恩
Owner INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap